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ABSTRACT 
SLEEP PATTERNS, URINARY LEVELS OF MELATONIN AND SUBSEQUENT WEIGHT 
CHANGE IN THE WOMEN’S HEALTH INITIATIVE OBSERVATIONAL STUDY 
MAY 2016 
NICOLE M. BARRON, B.S., CALIFORNIA UNIVERSITY OF PENNSYLVANIA 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Professor Susan R. Sturgeon 
 
Results from prospective studies examining associations between sleep duration and weight 
gain have been mixed. Melatonin has been hypothesized to mediate the association between 
sleep duration and weight/body composition. In cross-sectional studies, aMT6s has been shown 
to be inversely associated with weight/body fat percentage. We examined associations between 
baseline sleep duration, insomnia status, aMT6s levels with weight/body fat percentage through 
6 years, utilizing a subset 690 women who participated in a breast cancer case-control study 
nested within the WHI-OS. Multivariable and mixed-effects regression was used to calculate 
beta-coefficients and 95% confidence intervals. Cross-sectional analyses showed urinary 
aMT6s levels were inversely associated with BMI and body fat percentage. No associations 
were observed between sleep patterns and measures of adiposity. The prospective relationship 
between urinary aMT6 levels and weight/body fat percentage was complex.  Age-adjusted 
mixed models show an association in the interaction term between year and aMT6s with body 
fat percentage (βinteraction:0.09, p<0.01) and a marginally significant association with weight 
(βinteraction:0.16, p=0.07), demonstrating the influence of baseline aMT6s and time on changes in 
outcome. Women with higher baseline aMT6s had a trajectory of increased body fat percentage 
and weight gain steepest between baseline and year 3, whereas women with lower baseline 
aMT6 levels had a trajectory of decreased body fat percent and weight between year 3 and year 
6. The prospective association between melatonin levels and adiposity measures was 
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unexpected. Future studies with objective measures of sleep and repeated measures of 
melatonin may shed light of possible explanations for our findings. 
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CHAPTER 1 
 
INTRODUCTION 
 
In the past four decades, the prevalence of obesity (body mass index (BMI) ≥30kg/m2) in 
the United States has nearly tripled, from 13% in 1960s to 36% in 2011-2014(1, 2). In 2011-
2014, the prevalence of obesity in U.S women aged 60 and older was 38.8% according to the 
National Center for Health Statistics (2). Obesity is associated with increased risk for 
cardiovascular disease, cancer, diabetes, and decreases in quality of life (3). Body fat 
distribution may be even more strongly related to embolic disturbances and cardiovascular 
morbidity and mortality than BMI (4).  
Temporal increases in the prevalence of insufficient sleep are also hypothesized to have 
contributed to the obesity epidemic (5). Laboratory and animal studies have shown that blood 
leptin levels have specific patterns of secretion, with peaks during sleep. Shortened sleep 
results in decreased leptin circulation and increased ghrelin, which is associated with increased 
appetite and caloric intake (6). Based on the National Health Interview Survey, nearly 30% of 
adults reported less than the optimal sleep of 7-8 hours per day in 2005-2007 (7). Increases in 
sleep insufficiency may reflect modern society with its long working hours, shiftwork, widespread 
use of artificial lighting and technology use around the clock (8).  
Results from prospective studies of adults that have examined the association between 
sleep duration and weight gain have been mixed. Many have found shorter sleep durations to 
be associated with weight gain over time (9-15), while others have not (16-19). Results from the 
most recent studies that considered a women’s menopausal status and performed a separate or 
stratified analysis in pre- and post-menopausal women are presented in Table 1. A study 
investigating sleep duration, weight change, and obesity was conducted among 2,269 women in 
Spain aged 60 years and above (12). Sleep duration was self-reported and weight was 
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measured during a home-based personal interview. Over a 2 year follow-up period, they found 
women who reported 5 hours or less of sleep  of sleep were more likely to gain weight 
≥5kg,than average (7 hours) sleepers (OR:3.41 95%CI:1.34,8.69) (12).  They also observed an 
increased frequency of gaining ≥5kg among women sleep for 8 and 9 hours nightly than 
average sleepers (OR:3.03 95%CI:1.29,7.12) and (OR:3.77 95%CI:1.55,9.17), respectively.  
This study was unique in that it adjusted for depression status, chronic diseases, light at night, 
and intentional weight loss in analysis (12). Overall, evidence also suggests a link between 
greater than eight hours of sleep and weight gain. In agreement with Lopez-Garcia, et al (2008), 
there was a U-shaped relationship between sleep duration and weight in cross-sectional 
analyses in a Nurses’ Health Study that examined short sleep with weight gain in 68,183 women 
where those sleeping for ≥9 hours had a higher baseline weight (68.2kg), as compared to 
women sleeping for 7 hours (67.0kg) (10, 12).  
Research suggests that sleep duration is also associated with body composition. In a 
recent meta-analysis of 21 cross-sectional studies published from 2007-2013, sleep duration 
was negatively correlated (r:-0.10) with waist circumference, a marker of abdominal obesity 
(20). Some longitudinal evidence suggests that short sleep may be associated with greater 
abdominal obesity or visceral fat gain than average duration (7 hours) of sleep longitudinally, 
even after adjustment for body weight (11, 21, 22). Adult participants in the Quebec Families 
Study (men and women aged 18-65 years) were assessed at baseline and again at year 6 for 
sleep duration and visceral adipose tissue. Study results revealed that those participants who 
reported sleep duration ≤6hours or ≥9hours as compared to those reporting 7-8 hours at 
baseline gained significantly more visceral fat over 6 years (23.4cm2, 20.2cm2, and 14.1cm2, 
respectively) (21). 
There has been limited research on the possible association between insomnia and 
measures of body weight and composition. The results of studies have been mixed with some 
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clinical studies suggesting no evidence of increased body weight in individuals with insomnia 
whereas a few studies have suggested increases in appetite hormones and weight gain 
associated with insomnia in a mixed-sex population (23-25). A study conducted among male 
and female clinically diagnosed insomnia participants with a mean age of 42.2 years observed a 
negative correlation between poor sleep quality and BMI (r:-0.023) (24). 
Melatonin is a circulating hormone known to rhythmically regulate the sleep-wake cycle 
over 24 hours, with its highest concentration typically seen between 2-3am (26). Circadian 
rhythm disruption has been extensively examined and found to be associated with numerous 
factors including sleep duration, insomnia, and melatonin (27). Lower melatonin levels have 
been associated with shorter sleep duration in mixed-gender populations (28), and melatonin 
has been hypothesized to mediate the effect of sleep duration on body weight (29-31). While 
melatonin is more commonly thought to influence sleep and mood, it was thought that it may in 
turn influence insomnia. Insomnia is difficult to define as it is largely based on subjective 
complaints (32). The DSM-IV and ICD-10 code defines diagnosis of insomnia based on 
responses to the Pittsburgh Sleep Quality Index (33) and Insomnia Severity Index (34) listing 
complaints of difficulty initiating, maintaining, and non-restorative sleep. However, to date, there 
has been no compelling evidence that symptoms of insomnia are related to melatonin levels 
(35). Until this point, there have been no prospective studies to evaluate not only sleep duration 
and insomnia, but also baseline urinary levels of melatonin metabolite as a predictor of weight 
gain or fat mass in post-menopausal women.  However, six cross-sectional studies have 
examined urinary melatonin levels and BMI or weight (36-41).   
The only cross-sectional study that examined urinary melatonin levels as a predictor of 
change in weight was by Ramin and colleagues in the Nurses’ Health Study II cohort (41). They 
examined information obtained from 1,343 woman aged 32 to 53 years to investigate the 
association of early to mid-life body size with urinary aMT6s levels among night shift workers. 
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Women who gained more than 20kg since age 18 had lower concentrations of urinary aMT6s 
(36ng/mg) compared to women who reported gaining 5kg-20kg (42ng/mg) and women reporting 
gaining less than 5kg (45ng/mg), respectively. Adjustments in this analysis were made for age 
at urine collection, first-morning urine, batch, number of pack-years smoked, parity, physical 
activity in MET-hours per week, and night shift work in 2 weeks prior to urine collection (41). 
Neither sleep duration nor insomnia were considered in the analysis.  
To investigate the associations between baseline sleep duration, baseline insomnia 
status, baseline melatonin levels and weight changes/body fat percentage changes over time 
we analyzed a subset of women who participated in a breast cancer case-control study nested 
within the Bone Density Substudy in the WHI OS. We hypothesized that through 6 years of 
follow-up, women who slept for less than or more than 7 hours a night at baseline would have 
greater increases in weight and body fat percentage than women who slept for 7 hours a night, 
that women classified as having insomnia at baseline would have greater increases in weight 
and body fat percentage than women who were not classified as having insomnia, and that 
women with lower levels of mean aMT6s at baseline would have greater increases in weight 
and body fat percentage than women with higher levels of mean aMT6s at baseline. 
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CHAPTER 2 
METHODS 
Study Population 
The WHI-OS consists of 93,676 postmenopausal women who were 50-79 years of age at the 
time of their enrollment. They were recruited through the use of community-based methods at 
40 U.S. clinical centers from 1994 to 1998 (37). Women were excluded from participation if they 
had a condition that would encumber study compliance (issues with substance abuse or 
dementia, etc.), a condition with a less than 3 year predicted survival, or did not plan to reside in 
the area for at least 3 years (42). A baseline screening conducted by a medical professional and 
an extensive questionnaire was completed by each woman after study enrollment and annual 
questionnaires were sent out via mail to collect updated information on selected exposures and 
medical outcomes (37). The bone density sub-study of the WHI-OS was conducted in three 
clinical sites (Pittsburgh, Birmingham, and Tucson). DXA measurements were collected at 
baseline, year 3, and year 6 clinic visits on this subpopulation of approximately 10,000 women.  
Data from a previous nested case-control study on urinary levels of melatonin and breast 
cancer were used in this analysis. Study procedures have been described in detail elsewhere 
(37). Briefly, the study population of the nested case-control study was identified using women 
who were participants in a bone density sub-study of the WHI-OS enrolled at three clinical 
centers and also provided a urine specimen at baseline. The initial study population was 
comprised of 852 women, of whom 284 were breast cancer cases and 568 were controls (37). 
Women who had creatinine-standardized aMT6s concentrations and sleep pattern measures 
available at baseline and BMI (n=690) and percentage body fat (n=684) measures reported at 
baseline were included in our primary analysis. 
Sleep Duration Assessment 
Sleep duration was assessed at baseline using the question “About how many hours of sleep 
did you get on a typical night during the past 4 weeks?” (42, 43). There were six categories of 
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responses coded from 0 (most hours slept) to 5 (least hours slept). The response options 
included 10 or more, 9, 8, 7, 6, 5 or less hours (43). These response categories were collapsed 
to “6 hours or less”, “7 hours”, and “8 hours or more” for data analysis. 
Insomnia Assessment 
Insomnia was assessed at baseline using the Women’s Health Initiative Insomnia Rating Scale 
(43). The questions were designed to assess sleep habits and insomnia, with each being scored 
between 0 and 4, for an overall possible score of 20. A score of 9 or above is considered 
evidence for insomnia. The first four questions assessed the frequency of occurrence over the 
last four weeks. The questions, “Did you have trouble falling asleep,” “Did you wake up several 
times at night,” “Did you wake up earlier than you planned to,” and “Did you have trouble getting 
back to sleep after you woke up too early,” had five potential responses which included no, less 
than one weekly occurrence, 1-2 weekly occurrences, 3-4 weekly occurrences, 5 or more 
weekly occurrences, that corresponded to participants’ sleep experiences.. The fifth question 
assessed the quality of sleep over the past four weeks, with response options of “very sound or 
restful,” “sound or restful,” “average quality,” “restless,” and “very restless” (37). This 5-question 
rating scale has been validated through its use in several studies and comparing the results to 
the results the findings of validated sleep quality and insomnia rating scales (43). 
Melatonin Assessment 
With a half-life of 35 to 50 minutes, serum melatonin undergoes rapid metabolism in the liver 
resulting in the primary urinary metabolite, 6-sulphatoxymelatonin (aMT6s) (26). Due to this 
metabolism, aMT6s is usually measured via a single morning urine sample or samples collected 
over a 24 hour period. Both methods adjust samples for creatinine to account for differences in 
urine concentration. WHI collected first morning voids. Urinary 6-sulfatoxymelatonin (aMT6s) 
was assessed through a competitive ELISA (Buhlmann Laboratories AG) and were adjusted for 
creatinine levels to control for urine concentration (37). Concentration of urinary creatinine was 
determined through colorimetric analysis in ng/mg. In total, 40 masked duplicates were included 
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across three batches. The intra-assay coefficient of variation for unadjusted melatonin levels 
were 12.5% and 12.7% and the intra-assay coefficient of variation for unadjusted creatinine 
levels were 9.1% and 5.8% (37). 
Weight Assessment 
Weight was measured in kilograms and height was measured in meters by trained personnel at 
the WHI clinic visits at or near enrollment, at year 3 and year 6 using a calibrated balance beam 
scale (42). These variables were analyzed continuously. Body Mass Index for each collection 
time was calculated from weight and height measures. This variable was categorized as “normal 
weight” (<25kg/m2), “overweight” (25 to <30kg/m2), and “obese” ≥30kg/m2). 
Percentage Body Fat Composition Assessment 
 A dual energy X-Ray absorptiometry (DXA) scan was used to measure body composition at 
baseline and at years 3 and 6 of follow-up (42). The body composition assessments provide 
data on the components that make up a person’s weight that is more informative then BMI 
measures alone in that the DXA scan noninvasively assesses percentage body fat. This 
assessment provides individualized information on the distribution and composition of fat (21). 
The WHI corrected form of this variable was utilized, as it flagged and accounted for movement 
or other obstructed appearance in initial scan and reported a repeated the measure if necessary 
(44). This variable was measured continuously. All women had their DXA scans completed on 
comparable versions of the Hologic QDR-2000 bone denisitometer scanner at each time point 
(44). 
Covariate Assessment 
 
Information was available at baseline on the following factors: age, ethnicity (White, 
Black/African American, Other), education (<high school, high school to <college, college to 
<post-graduate study, ≥post-graduate study or degree), family income (<$35,000, $35,000-
$75,000, ≥$75,000, unknown), employment status (not employed, employed), marital status 
(never married, widowed/divorced/separated, married/marriage-like relationship), personal 
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history of diabetes, personal history of stroke, alcohol consumption (non-drinker, former drinker, 
<1 drink/month, <1 drink/week, 1-<7 drinks/week, ≥7 drinks/week), energy expenditure from 
physical activity (METS hr/week), cigarette smoking (never, past, current), caffeine consumption 
(mg), daily caloric intake (tertiles, kcal/day), modified healthy eating index (tertiles, 0-100 scale, 
closer to 100 indicates better adherence to dietary recommendations), depression status (0-1 
scale, ≥0.6 signifies depression), social strain (4-20 scale, closer to 20 signifies more social 
strain), physical functioning (0-100 scale, closer to 100 signifies more favorable physical 
function) and emotional limitations (0-100 scale, closer to 100 signifies more favorable 
emotional state). Information for each covariate was obtained at baseline from its corresponding 
questionnaire. All variables above were selected for inclusion based on their known relationship 
with melatonin and/or sleep patterns and weight and/or body composition or due to prior their 
inclusion in literature evaluating similar exposure and outcome associations (10, 15, 36-41, 45, 
46). 
Statistical Analysis 
Initial summary statistics and frequency distributions were conducted for all variables at 
baseline. Chi-square or Analysis of variance (ANOVA) were performed as appropriate to 
examine the distribution of BMI, weight, body fat percentage, and covariates by sleep duration, 
insomnia or aMT6s . Due to skewed urinary melatonin metabolite data, creatinine-adjusted 
aMT6s values were log-transformed and geometric means reported. 
Overview 
We conducted three main analyses for each of the three exposures (sleep duration, insomnia, 
and aMT6s) with the two outcomes (BMI/weight and body fat percentage). Initially we assessed 
the association between the exposures at baseline and the outcomes at baseline. We followed 
the baseline analysis by assessing the association of baseline exposures with outcomes at year 
6, adjusting for baseline outcome and covariates. Finally, we utilized linear mixed-effects 
models that incorporate the repeated measures of weight and body fat percent, from baseline, 
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year 3 and year 6, to assess their changes associated with sleep duration, insomnia, and 
aMT6s through the 6 years of follow-up. 
Baseline 
Linear regression was used to assess the relationship of sleep duration categories, insomnia 
score, and adjusted urinary melatonin metabolite concentrations on weight and percentage 
body fat at baseline. Multivariable linear regression models were used to assess the relationship 
between the exposures and outcomes after adjustment for potential confounders as determined 
from bivariate analysis (p<0.1) and biological importance from prior literature (15, 45). Due to 
the large number of potential confounders, models were created and run with subsets of related 
potential confounders were grouped to assess the change in effect of that model subset. If the 
change in effect of a particular model was greater than 10%, then the confounders in that model 
were further investigated. Confounders including age (Model 1), sleep duration, insomnia, 
aMT6s (Model 2, as appropriate), education, ethnicity, marital status (Model 3), HEI score, daily 
caloric intake, weekly energy expenditure (Model 4), depressive symptoms, physical functioning 
and emotional limitations constructs (Model 5), smoking, alcohol intake (Model 6), personal 
history of diabetes or stroke (Model 7), with all models after Model 1 being adjusted for age. A 
final was fit including covariates from all models. To assess potential mediation, an additional 
model was fit excluding sleep duration, insomnia, or aMT6s, as appropriate. Only subjects with 
information available on all exposure, outcome, and covariates were included in the models and 
analysis was repeated for all exposures and body composition variables. Beta coefficients with 
95% confidence intervals and p-values were presented.  
Year Six 
As with linear regression analyses conducted on the baseline outcomes, the relationship 
between sleep duration categories, insomnia score, and adjusted urinary melatonin metabolite 
concentrations on weight and percentage body fat at year 6 was completed in the same 
manner. Analysis for outcome measures at year 6 were conducted using the same modeling 
10 
 
process and groupings, with the addition of an age and baseline weight/body fat percentage 
adjusted model and all subsequent models being adjusted for both age and baseline 
weight/body fat percentage. Only subjects with information available on all exposure, outcome, 
and covariates were included in the models. Analysis was repeated for all exposures and body 
composition variables. Beta coefficients with 95% confidence intervals and p-values were 
presented. 
Mixed Models 
The relationship between sleep duration, insomnia status, and aMT6s levels with repeated 
measures of weight and body fat percentage was assessed using linear mixed-effects 
regression models. Intercepts and slope were random and an interaction term between year 
and sleep duration, insomnia status, or aMT6s levels, as appropriate, was added to each model 
to assess the influence of the exposure on change in body fat percentage or weight. The same 
series of models used in the year 6 linear regression analysis was also utilized for the linear 
mixed models. This secondary analysis was limited to 490 study participants who had complete 
data available for baseline measures of sleep duration, insomnia status, aMT6s, and pertinent 
covariates, as well as, weight and body fat percentage at all three time points (0,3,6). 
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CHAPTER 3 
RESULTS 
A total of 690 women who participated in the original breast cancer nested-case control 
study had sleep duration, insomnia, and aMT6s data available, as well as complete data on BMI 
and covariates and 684 had data available for all three exposures, body fat percentage and 
covariates. The average age of study participants was 63 years at baseline. As shown in Table 
2, nearly 62% were overweight or obese and the average percentage body fat was 43%. 
Approximately 33%, 41%, 25% of the population reported sleeping for 6 or less hours, 7 hours, 
and 8 or more hours, respectively. Nearly 30% of the participants met the criteria for insomnia 
and the mean creatinine-adjusted aMT6s level was 16.1ng/mg. Overall, the majority of women 
where white, married, and had had some college level education. Few women were current 
smokers and the majority reported current consumption of alcohol. 
In total, 56% of participants were not currently employed and nearly half reported 
earning less than $35,000 annually. Few women had a prior diagnosis of diabetes, stroke, or 
myocardial infarction. The mean total daily caloric intake was 1539.6±662.8kcal/day and the 
average modified healthy eating index score of 68.6±10.5, where a score closer to 100 indicates 
better adherence to dietary guidelines. Overall, 20% of the population had a mean energy 
expenditure from moderate physical activity falling within the recommended range of 8.3 to 16.7 
METS hr/wk (47) as opposed to 51% falling below this recommendation. The majority of the 
women did not exhibit depressive symptoms (88.1%) and had mean physical functioning and 
emotional limitations construct scores of 80.6 and 84.5 respectively, where scores closer to 100 
indicate a more favorable health state.  
Sleep Duration 
The distribution of baseline sociodemographic and lifestyle characteristics by sleep 
duration category are presented in Table 3. Women in this category tended to be 60-69 years of 
age, fell into the “normal weight” category for BMI, had a higher mean aMT6s as compared to 
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other sleep duration categories, and did not report insomnia or depressive symptoms. They had 
similar body fat percentages and higher scores for both the physical functioning and emotional 
limitations constructs as compared to other sleep duration categories. The majority of women 
falling into the lowest tertile of HEI score slept for 6 hours or less nightly and those women 
falling into the higher tertiles slept for 7 hours nightly.  
Results for all multivariable linear regression models of sleep duration for body mass 
index and body fat percentage at baseline are presented in Tables 4 and 5. We did not observe 
a statistically significant association between sleep duration (7 hours as reference) with 6 hours 
of sleep or less (β -0.06, 95%CI:-0.08-0.20) or 8 hours of sleep of more (β 0.06, 95%CI:-0.09-
0.20) with body mass index in the age-adjusted model. We also did not observe a statistically 
significant association for sleep duration (7 hours as reference) with 6 hours of sleep or less (β -
0.05, 95%CI:-0.18-0.09) or 8 hours of sleep of more (β 0.02, 95%CI:-0.12-0.16) with body mass 
index in the fully-adjusted model. In the age-adjusted and fully-adjusted models for sleep 
duration and body fat percentage, we did not observe an association of sleep duration (7 hours 
as reference) in 6 hours of sleep or less (β -0.45, 95%CI:-1.73-0.84) or 8 hours of sleep or more 
(β 0.21, 95%CI:-1.19-1.60)  [age-adjusted] and 6 hours of sleep or less (β -1.09, 95%CI:-2.32-
0.13) or 8 hours of sleep of more (β 0.13, 95%CI:-1.15-1.40) [fully-adjusted] with body fat 
percentage. In tables 6 and 7, we examined sleep duration and weight and body fat percentage 
at year 6 and observed no association (p>0.05).  
Insomnia 
In Table 8, we observe that overall most women did not have insomnia (n=530). The 
majority of women classified as having insomnia fell into the sleep duration category of 6 hours 
or less. Women classified as having insomnia had lower scores for both the physical functioning 
and emotional limitations constructs as compared to women with no insomnia classification (75 
& 73 vs. 83 & 90). The prevalence of depressive symptoms also varied by insomnia status. 
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Results for multivariable linear regression models of insomnia status for body mass 
index and body fat percentage (baseline) are presented in Table 9. In both our age-adjusted 
and fully-adjusted multivariable models of insomnia status, with no insomnia serving as our 
reference group, we observed no statistically significant association of insomnia (β 0.04, 
95%CI:-0.09-0.17) and (β -0.02, 95%CI:-0.15-0.11) with body mass index. We also did not 
observe an association in our age-adjusted or fully-adjusted models for insomnia (β 0.45, 
95%CI:-0.75-1.65) and (β 0.32, 95%CI:-0.88-1.52) with body fat percentage. 
We also explored the association between insomnia status and weight and body fat 
percentage at year 6. The results of these analyses are presented in Table 10. No association 
was observed between insomnia status and weight at year 6, or insomnia status and body fat 
percentage at year 6 in our age-adjusted or fully-adjusted models.  
Melatonin 
Analysis of urinary aMT6s with covariates yielded some variations in mean aMT6s within 
covariate categories (Table 11). Overall, we observed a decrease in mean aMT6s as age and 
BMI categories increase. White women had higher mean aMT6s than black women and women 
of other ethnicities, 11.9ng/mg, 8.3ng/mg, and 9.9ng/mg respectively and women who were 
married had higher mean aMT6s than women in other categories. Women with diagnosis of 
diabetes had a substantially lower mean aMT6s compared to women with no diagnosis of 
diabetes, 6.8ng/mg and 11.6ng/mg. Women who were current drinkers had increased mean 
aMT6s than non- and former drinkers (~12.3ng/mg vs 10.5ng/mg and 9.4ng/mg). Mean aMT6s 
was significantly correlated with percentage body fat and the physical functioning construct (-
0.164 and 0.124). Overall, 32% of women lost more or less than 2.3kg (equivalent to 5lbs) over 
the 6 years of follow-up. The women making up these groups also had urinary aMT6s levels of 
13.4 and 14.9ng/mg, respectively, as compared to 21.1ng/mg for women with no change in 
weight.  
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Results for multivariable linear regression models of log-transformed aMT6s for body 
mass index and body fat percentage (baseline) are presented in Table 12. In the age-adjusted 
model we observed that there was no deviation from the unadjusted model. In our fully-adjusted 
multivariable model for body mass index, we observed a significant inverse association between 
aMT6s and BMI. For each 1 unit increase in log aMT6s (ng/mg of creatinine), BMI decreased by 
0.09 kg/m2, holding all other variables constant. The results of this model can be translated to a 
10 unit increase in aMT6s results in a decrease in BMI of 0.1 kg/m2, holding all other variables 
constant when considering the non-log transformed adjusted urinary melatonin variable. In our 
fully-adjusted multivariable model for body fat percentage, we also observed a significant 
inverse association between aMT6s and body fat percentage. For each 1 unit increase in log 
aMT6s (ng/mg of creatinine), body fat percentage decreased by 0.63%, holding all other 
variables constant. These results translate to a 10ng/mg increase in aMT6s results in a 
decrease in body fat percentage of 0.5%, holding all other variables constant in the fully-
adjusted model using the non-log transformed adjusted urinary melatonin. There was no strong 
evidence of potential confounding in either model. 
We also explored the association between aMT6s and body weight and body fat 
percentage at year 6. The results of mean aMT6s for body weight and body fat percentage 
(year 6) are presented in Table 13. In the age-adjusted model for body weight, we found a 
significant inverse association between log-transformed aMT6s and body weight (β:-1.77 
95%CI:-3.35,-0.19). This association was no longer present upon adjustment for baseline body 
weight in subsequent models. No association was observed between aMT6s and body fat 
percentage at year 6 in our age-adjusted or fully-adjusted models.  
Mixed Models 
Sleep duration at baseline was not found to be associated with body fat percentage or its 
interaction with follow-up time in any of the models (data not shown), including the full model (β: 
-0.06 (0.04), p=0.13). Sleep duration at baseline was not found to be associated with weight or 
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its interaction with follow-up time in any of the models, including the full model (β:-0.09 (0.10), 
p=0.37). Insomnia status at baseline was not found to be associated with body fat percentage or 
its interaction with follow-up time in any of the models, including the full model (β: 0.08 (0.07), 
p=0.21). Insomnia status at baseline was also not found to be associated weight or its 
interaction with follow-up time in any of the models, including the full model (β: 0.04 (0.18), 
p=0.82).  
Mixed models analyzing weight and body fat percentage according to baseline log-
adjusted aMT6s are presented in Figures 1 & 2. Log-adjusted aMT6s at baseline was 
significantly associated with body fat percentage change over time, as was its interaction with 
follow-up time (p<0.01). The interaction term remained significantly associated with body fat 
percentage after all model adjustments and in the full model. Therefore, for each 1 unit increase 
in log aMT6s (ng/mg of creatinine), body fat percentage increased by 0.09% per year. Log-
adjusted aMT6s at baseline was found to be significant with weight (p<0.05) and its interaction 
with follow up time was marginally significant (p=0.07). The interaction term remained 
marginally significant throughout all model adjustments and in the full model. Therefore, for 
each 1 unit increase in log aMT6s (ng/mg of creatinine), body weight increased by 0.16kg per 
year. 
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CHAPTER 4 
DISCUSSION 
In our study, we found no association in either cross-sectional or prospective analyses 
between sleep duration and BMI/body weight or body fat percentage. We also found no 
evidence in either cross-sectional or prospective analyses between insomnia and BMI/body 
weight or body fat percentage. Cross-sectionally, we observed a statistically significant inverse 
association between urinary levels of melatonin metabolite (aMT6s) and measures of body 
mass index and composition where increased baseline levels of aMT6s were associated with a 
slightly higher BMI and slightly higher body fat percentage. We found no evidence of an 
association between baseline aMT6s levels and body weight at year 6. However, we observed a 
borderline statistically significant positive association between aMT6s and body fat percentage 
at year 6 where higher levels of baseline aMT6s were associated with increased body fat 
percentage at year 6. 
Although some prospective studies observed statistically significant associations 
between ≤6 hours sleep duration with an increase in weight (9-15), other studies have been null 
(16-19). In general, studies that have examined the relationship between short sleep duration 
and weight gain have been stronger in adolescents and children (48), while the association 
between sleep duration and weight gain has not been consistently suggested in older adults 
(10, 12, 16) and may diminish with age . Furthermore, studies have suggested that the 
association with weight gain may be stronger in individuals who weigh less (49, 50).  At entry, 
the mean age of the women in our study at entry was 63.5 years and over 60% of the women in 
our study were overweight or obese.  The follow-up time of our study was also relatively short 
which may have made it more difficult to find an association. When comparing it to studies of 
older individuals, the women in a study conducted by Lopez-Garcia, et al (2008) who had a 
mean age of 72.1 years and over 78% who were considered obese, with 7.5 years of follow-up 
(12) and Xiao, et al (2013) who were 51-72 years old and 20% who were considered obese, 
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with 2 years of follow-up (15), found associations with short sleep duration (≤5 hours) in which 
the longer follow-up time and younger study population, respectively, could have influenced our 
inability to find an association(12, 15). Long sleep durations and weight gain have been more 
inconsistent (6, 10, 11). 
Few studies have looked at the association between sleep duration and body fat 
percentage. Results from a prior cohort study of 276 male and female participants, aged 21 to 
64 years, that focused on sleep duration and body composition changes over 6 years, 
suggested that shorter (5-6 hours) and longer (9-10hours) sleep duration is associated with an 
increased body fat percent as compared to those sleeping 7-8 hours (11). 
Similar to our findings for insomnia, two prior studies observed null results (24, 25) 
whereas Crönlein et al. (2015) observed a significantly lower weight among women with 
insomnia in a cross-sectional study conducted in a well-defined large clinical sample 
predominantly of older women (82% women vs. 18% men).  
We observed a cross-sectional association between urinary levels of melatonin 
metabolite (aMT6s) and body mass index, where increased baseline levels of aMT6s were 
associated with a slightly lower BMI. In agreement with our results, other cross-sectional studies 
have found a significant inverse association between urinary melatonin metabolite and BMI (36-
41, 51, 52). A study conducted among 1,343 female night-shift workers selected from the 
Nurses’ Health Study II aged 32-53 years found women in the lowest quartile of aMT6s had 
higher BMI than women in the highest quartile of aMT6s (41). This same study also investigated 
the association of early to mid-life body size with urinary aMT6s levels and found no association 
between current aMT6s levels and average somatotype in childhood, however an inverse 
association between baseline aMT6s and waist circumference was observed. Moreover, studies 
have suggested that adult BMI may influence melatonin’s’ mediation of circadian rhythms more 
so than body size earlier in life (41). One potential biological mechanism proposed to link 
melatonin with weight and BMI is related to the presence of melatonin in the liver. Melatonin 
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may be involved in the accumulation of fatty acid-induced triglycerides in the liver, preventing an 
increase in the levels of circulating triglycerides (53, 54). Increases in the levels of circulating 
triglycerides has been linked to increased food intake and subsequent weight gain (53).  
While we observed the presence of a significant cross-sectional association between 
aMT6s and BMI and body fat percentage, we failed to observe an association in prospective 
analyses. This may be due our relatively short period of follow-up, which may have hindered our 
ability to observe the long-term influence of melatonin on weight and body fat percentage. 
Another possible explanation is the age-related decrease of melatonin levels of women in this 
study population may have less of an impact on weight and body fat percentage, as compared 
to younger women.   
 Women with higher baseline melatonin levels had an unexpected trajectory of increased 
body fat percentage and weight gain which was steepest between baseline and year 3, women 
with intermediate baseline melatonin levels had relatively stable body fat percentage and weight 
over time, and women with lower baseline melatonin levels had a trajectory of body fat 
percentage and weight loss, which was steepest between year 3 and year 6. Dissimilar to the 
inverse association observed in our cross-sectional analyses, as well as, prior literature, mixed 
models analysis revealed higher levels of aMT6s at baseline were not suggestive of a clear 
overall decrease body fat percentage and weight during follow-up. Our study had only single 
baseline measure of urinary melatonin levels and thus it is difficult to know if changes in 
melatonin over time accounted for the complex patterns observed over time. Overall, 
differences were small and results may have occurred by chance. 
To our knowledge, this is the first prospective study of post-menopausal women to 
examine the association of baseline urinary melatonin metabolite, sleep duration and insomnia 
status with body fat percent and weight over time. The prospective nature of the study 
strengthens our analyses, as does the in-clinic measures of weight, height, and body fat 
percent, the validated sleep and insomnia questionnaires, the collection and analysis of urine for 
19 
 
aMT6s levels prior to evaluation of weight and body fat percentage, and the extensive data that 
was collected on potential confounding variables.  
This study is limited by the self-report nature of sleep duration and no clinical diagnosis 
of insomnia, but rather self-report responses to a series of questions that are scored to assign 
insomnia status. The self-reported nature of both the sleep duration and insomnia variables is 
subjective and the measure was only taken once and was based upon sleep duration and 
insomnia habits in the past 4 weeks only, therefore non-differential misclassification of exposure 
could have influenced our null findings through underestimation of effect estimates. A study by 
Kripke, et al, conducted on 350 women within the WHI-OS, observed a relatively weak 
correlation (r: 0.37) between responses to the WHI questionnaire and results of 7-nights of wrist 
actigraphy, which further suggests that our results may be underestimates resulting from non-
differential misclassification of exposure (55).  
Sleep duration responses from self-report questionnaires were collapsed from the six 
original WHI categories into 3 sleep duration categories for meaningful analysis in this study 
population. This category collapse eliminated our ability to examine associations in shorter (≤5 
hours) or longer (≥9 hours) sleep duration categories with sleep duration similar to those 
observed in previous literature (10, 12, 15, 22). Misclassification of this nature is likely to have 
biased our results toward the null.  
Urinary melatonin metabolite was ascertained through the first morning midstream spot 
void at baseline. This method is subject to misclassification if a woman if a women had an 
overnight void prior to the first morning void or if a sample collected at a later time that was 
mislabeled as the first morning void resulting in aMT6s measures that are an underestimate of 
the overnight peak. Additionally, the single measure of aMT6s may be subject to intra-person 
variation, therefore some women may have their aMT6s level misclassified. If this non-
differential misclassification occurred, our results would be underestimated and the bias would 
be toward the null. As WHI protocol instructed women as to the importance of first morning void 
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collection and due to first morning aMT6s concentrations remaining fairly stable with repeated 
measures over several years (ICC:0.72, 95%CI: 0.65, 0.82), misclassification of this type is of 
minimal concern (42, 56).  
The parent nested-case control study considered the risk of aMT6s on breast cancer 
(37). We acknowledge that a large proportion of our study population developed breast cancer 
during follow-up, and this breast cancer diagnosis may influence our exposure and/or outcome 
measures. To evaluate the potential impact of breast cancer status, we conducted separate 
analyses in controls which showed results similar to the overall study population. We are further 
reassured by results of our analyses in the overall study population behaving similarly to prior 
literature. 
In summary, the link between self-reported sleep duration and subsequent weight gain 
and, to a lesser extent, body composition has been studied in a number of studies with mixed 
results. Future studies should focus on the relationship between objective sleep measurements 
and weight and body composition.  Further work is also needed to understand the inverse 
association between urinary levels of melatonin and obesity which has been observed in a 
number of cross-sectional studies. 
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Table 1. Most recent sleep duration and weight studies that consider menopause status in women 
Author, 
year 
Study 
Population 
Exposure & 
Assessment 
Outcome & 
Assessment 
Effect Estimate 
Applehans, 
2013 
SWAN Sleep 
Study, 310 post-
menopausal 
women 
Avg follow-up: 
3yrs 
 
Sleep; 3 self-
report by 
actigraphy & 
sleep diary 
assessment  
BMI calculated 
from Height & 
Weight; 
measured on 
calibrated scale 
0.06 (95%CI: -2.28, 2.40), n=33 
Xiao, 2013 NIH-AARP Diet & 
Health Cohort 
Study, 40,201 
Women aged 51-
72 years 
Sleep duration; 
self-reported 2 
time points 
Weight change, 
self-report 
Weight gain  
<5hrs: 0.43kg (95%CI: 0.00, 0.86) 
 5-6hrs: 0.23kg (95%CI: 0.08, 0.37) 
≥9: no association 
 as compared to 7-8 hours 
Lopez-
Garcia, 
2008 
Spanish 
Population-
based, 2,269 
women baseline 
≥60 years 
Sleep duration, 
home-based 
personal  
interview 
Weight gain, self-
report 
Weight gain >0.1kg≤5hrs (OR:3.41 
95%CI:1.34, 8.69) 
6 hours: no association 
8hrs: (OR:3.03 95%CI:1.29, 7.12) 
9hrs: (OR:3.77 95%CI 1.55, 9.17) 
<9hours : no association 
as compared to 7 hours  
Patel, 2006 Nurses’ Health 
Study; 68,183 
women aged 39-
65 years 
Sleep duration, 
self-reported in 
the 1986 
questionnaire 
(baseline) 
Weight gain, self-
reported 
biennially 
Weight  
≤5 hour: 2.47kg (95%CI:1.97, 2.98); 
6hrs: 1.24kg (95%CI:0.99, 1.29) as 
>7hrs of sleep:  no association 
compared to 7 hours, no association 
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Table 2. Baseline characteristics of study population in the Women’s Health 
Initiative, N=690 
Characteristics  Participants  
n (%) 
 Mean ± SD 
Urinary Melatonin Metabolite  
    aMT6s (ng/mg of creatinine) 16.5±12.6 
Sleep Duration  
    6 hours or less 229 (33.2) 
    7 hours 285 (41.3) 
    8 hours or more 176 (25.5) 
Insomnia Rating 6.6±4.4 
    No  (<9) 481 (69.7) 
    Yes (≥9) 209 (30.3) 
Age in years 63.2±7.1 
Body Mass Index (kg/m2) 27.9±6.1 
    Normal Weight (<25 kg/m2) 259 (37.5) 
    Overweight (25 to <30 kg/m2) 239 (34.6) 
    Obese (≥30 kg/m2) 192 (27.8) 
Body Fat Percentage 42.9±7.3 
    Missing (N) 16 
Fat Mass (kg) 31.6±11.4 
    Missing (N) 16 
Lean Mass (kg) 38.0±5.2 
    Missing (N) 16 
Weight (kg) 73.1±16.4 
Height (m) 1.6±0.1 
Education  
    Less than High School 46 (6.7) 
    High School to <College 229 (33.2) 
    College to <Post-graduate Study 239 (34.6) 
    ≥Post-graduate Study or Degree 179 (25.5) 
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Ethnicity  
    White (Non-Hispanic) 630 (81.1) 
    Black or African-American (Non-Hispanic) 93 (12.0) 
    Other 54 (6.9) 
Income Status  
    <$35,000 323 (46.8) 
    $35,000 - $75,0000 227 (32.9) 
    ≥ $75,000 90 (13.0) 
    Missing (N) 50 
Employment Status  
    Not employed 387 (56.1) 
    Employed 185 (26.8) 
    Missing (N) 118 
Marital Status  
    Never Married 26 (3.8) 
    Widowed/Divorced/Separated 212 (30.7) 
    Married/Marriage-like relationship 452 (65.5) 
Total Caloric Intake (kcal/day)  
   Tertile 1 (240.8-1250.4) 923.2±230.9 
   Tertile 2 (1251.1-1719.7) 1473.2±136.5 
   Tertile 3 (1721.6-6546.0) 2205.0±561.0 
Modified Healthy Eating Index  
   Tertile 1 (36.4-65.87) 56.5±6.8 
   Tertile 2 (65.88-74.74) 70.4±2.5 
   Tertile 3 (74.78-89.7) 79.3±3.2 
Prior Diagnosis of Diabetes  
     No 650 (94.2) 
     Yes 40 (5.8) 
History of Stroke  
     No 686 (99.4) 
     Yes 4 (0.6) 
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History of MI  
     No 672 (97.4) 
     Yes 18 (2.6) 
Cigarette smoking  
    Never 365 (52.9) 
    Former 277 (40.1) 
    Current 48 (7.0) 
Alcohol consumption  
    Non drinker 109 (15.8) 
    Former drinker 141 (20.4) 
Current drinkers  
    <1 drink per month 92 (13.3) 
    <1 drink per week 131 (19.0) 
    1 to <7 drinks per week 151 (21.9) 
    7+ drinks per week 66 (9.6) 
Caffeine Consumption (mg) 169.4±135.3 
Energy expenditure from physical activity (METSa hr/wk) 12.5±14.0 
Social Strain 6.4±2.5 
    Missing (N) 6 
Physical Functioning 81.0±19.5 
Depressive Symptoms 0.04±0.13 
    No  (<0.06) 610 (88.4) 
    Yes (≥0.06) 80 (11.6) 
Limitations due to emotional problems 84.1±30.3 
a METS (metabolic equivalent task scores)  
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Table 3. Sleep duration by study population characteristics in the Women’s Health Initiative, N=690 
Characteristic  6 hours or less 
N=229 
N (%) /Mean±SD 
7 hours 
N=285  
N (%) /Mean±SD 
8 hours or more 
N=176  
N (%) /Mean±SD 
P-value 
Age in years     
   ≤59 76 (33.2) 88 (30.9) 57 (32.4) >0.1 
   60-69 107 (46.7) 138 (48.4) 88 (50.0)  
   ≥70 46 (20.1) 59 (20.1) 31 (17.6)  
Body Mass Index (kg/m2)     
    Normal Weight (<25 kg/m2) 83 (36.3) 111 (38.9) 65 (36.9) >0.1 
    Overweight (25 to <30 kg/m2) 80 (34.9) 101 (35.4) 58 (33.0)  
    Obese (≥30 kg/m2) 66 (28.8) 73 (25.6) 53 (30.1)  
aMT6s(ng/mg creatinine) 2.4±1.0 2.5±0.9 2.5±1.0 >0.1 
Insomnia Rating     
    No 124 (54.2) 208 (73.0) 149 (84.7) <0.001 
    Yes 105 (45.8) 77 (27.0) 27 (15.3)  
Body Fat Percentage 43.1±7.9 42.8±7.1 43.2±7.6 >0.1 
Whole Body Fat Mass (kg) 32.0±12.5 31.4±10.9 31.5±10.7 >0.1 
Whole Body Lean Mass (kg) 38.7±5.5 37.7±5.2 37.5±4.8 0.08 
Education     
  Less than High School 19 (8.3) 18 (6.3) 9 (5.1) 
>0.1 
  High School to <College 87 (38.0) 94 (33.0) 48 (27.3) 
  College to <Post-grad Study 72 (31.4) 96 (33.7) 71 (40.3) 
  ≥Post-grad Study or Degree 51 (22.3) 77 (27.0) 48 (27.3) 
Ethnicity     
White (Non-Hispanic) 166 (72.5) 250 (87.7) 152 (86.4) 
<0.001 
Black or African-American  (Non-
Hispanic) 
46 (20.1) 17 (6.0) 17 (9.6) 
   Other 17 (7.4) 18 (6.3) 7 (4.0) 
Income Status     
    <$35,000 115 (54.5) 125 (47.2) 83 (50.6) >0.1 
    $35,000-<$75,0000 73 (34.6) 98 (37.0) 56 (34.2)  
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    ≥ $75,000 23 (10.9) 42 (15.8) 25 (15.2)  
Employment Status    
>0.1     Not employed 125 (65.8) 156 (67.2) 106 (10.7) 
    Employed 65 (34.2) 76 (32.8) 4 (29.3) 
Marital Status    
0.05 
Never Married 10 (4.4) 8 (2.8) 8 (4.6) 
     Widowed/Divorced/Separated 83 (36.2) 76 (26.7) 53 (30.1) 
Married/Marriage-like 
relationship 
136 (59.4) 201 (70.5) 115 (65.3) 
Total Caloric Intake (kcal/day)     
   Tertile 1 (168.1-1158.5) 89 (38.9) 94 (33.0) 47 (26.7) 
0.07    Tertile 2 (1159.4-1618.9) 65 (28.4) 103 (36.1) 62 (35.2) 
   Tertile 3 (1621.0-6497.7) 75 (32.7) 88 (30.9) 67 (38.1) 
Modified Healthy Eating Index     
   Tertile 1 (27.3-65.8) 100 (43.7) 75 (26.3) 55 (31.3) 
<0.001    Tertile 2 (65.9-74.7) 67 (29.3) 101 (35.4) 62 (35.2) 
   Tertile 3 (74.7-90.4) 62 (27.1) 109 (38.3) 59 (33.5) 
Prior Diagnosis of Diabetes     
     No 212 (92.6) 271 (95.1) 167 (94.9) >0.1 
     Yes 17 (7.4) 14 (4.9) 9 (5.1)  
Diagnosis of Stroke    
>0.1      No 228 (99.6) 283 (99.3) 175 (99.4) 
     Yes 1 (0.4) 2 (0.7) 1 (0.6) 
Diagnosis of MI    
>0.1      No 221 (96.5) 277 (97.2) 174 (98.9) 
     Yes 8 (3.5) 8 (2.8) 2 (1.1) 
Cigarette smoking    
>0.1 
    Never 124 (54.2) 147 (51.6) 94 (53.4) 
    Former 85 (37.1) 124 (43.5) 68 (38.6) 
    Current 20 (8.7) 14 (4.9) 14 (8.0) 
Alcohol consumption    >0.1 
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    Non drinker 39 (17.0) 43 (15.1) 27 (15.3) 
    Former drinker 52 (22.7) 51 (17.9) 38 (21.6) 
Current Drinkers    
    <1 drink per month 35 (15.3) 37 (13.0) 20 (11.4) 
    <1 drink per week 43 (18.8) 51 (17.9) 37 (21.0) 
    1 to <7 drinks per week 45 (19.6) 73 (25.6) 33 (18.8) 
    7+ drinks per week 15 (6.6) 30 (10.5) 21 (11.9) 
Caffeine Consumption (mg) 174.9±146.9 162.8±123.9 173.1±137.6 >0.1 
Energy expenditure from 
physical activity (METS hr/wk) 
13.3±16.5 12.4±12.2 11.8±13.1 >0.1 
Social Strain 6.6±2.7 6.4±2.5 6.2±2.3 >0.1 
Physical Functioning 78.2±22.2 83.2±16.6 81.0±19.7 >0.1 
Depressive Symptoms     
    No  (<0.06) 188 (82.1) 261 (91.6) 161 (91.5) 
<0.001 
    Yes (≥0.06) 41 (17.9) 24 (8.4) 15 (8.5) 
Limitations due to emotional 
problems 
77.9±35.1 89.1±24.8 84.1±30.2 0.09 
a METS (metabolic equivalent task scores) 
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^ Reference category: 7 hours 
Model 1 adjusted for age 
Model 2 adjusted for age, insomnia, and aMT6s 
Model 3 adjusted for age, education, ethnicity, and marital status 
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure 
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional 
limitations constructs  
Model 6 adjusted for age, smoking status, alcohol consumption  
Model 7 adjusted for age, diabetes, and stroke  
Model 8 adjusted for age, all variables from weight models 3-7 
Model 9 adjusted for age, all variables from weight models 2-7 
 
  
Table 4. Multivariable linear regression describing influence of baseline sleep duration on body 
mass index (kg/m2), N=690 
 Sleep duration, ≤6 hours^ Sleep duration, ≥8 hours^  
 β (95% CI) β (95% CI) P Value 
Unadjusted 0.06 (-0.08, 0.20) 0.06 (-0.09, 0.20) 0.609 
Model 1 0.06 (-0.08, 0.20) 0.06 (-0.09, 0.20) 0.617 
Model 2 0.03 (-0.11, 0.17) 0.07 (-0.08, 0.22) 0.683 
Model 3 -0.02 (-0.15, 0.12) 0.06 (-0.08, 0.21) 0.576 
Model 4 0.03 (-0.11, 0.17) 0.05 (-0.10, 0.20) 0.793 
Model 5 0.01 (-0.13, 0.14) 0.03 (-0.11, 0.17) 0.905 
Model 6 0.03 (-0.11, 0.16) 0.05 (-0.09, 0.20) 0.783 
Model 7 0.04 (-0.09, 0.18) 0.06 (-0.08, 0.21) 0.671 
Model 8 -0.04 (-0.18, 0.09) 0.02 (-0.12, 0.16) 0.680 
Model 9 -0.05 (-0.18, 0.09) 0.02 (-0.12, 0.16) 0.677 
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^Reference category: 7 hours 
Model 1 adjusted for age 
Model 2 adjusted for age, insomnia, and aMT6s 
Model 3 adjusted for age, education, ethnicity, and marital status 
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure 
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional 
limitations constructs  
Model 6 adjusted for age, smoking status, alcohol consumption  
Model 7 adjusted for age, diabetes, and stroke  
Model 8 adjusted for age, all variables from weight models 3-7 
Model 9 adjusted for age, all variables from weight models 2-7 
 
 
  
Table 5. Multivariable linear regression describing influence of baseline sleep duration on body 
fat percentage, N=684 
 Sleep duration, ≤6 hours^ Sleep duration, ≥8 hours^  
 β (95% CI) β (95% CI) P Value 
Unadjusted -0.44 (-1.73, 0.84) 0.21 (-1.18, 1.61) 0.650 
Model 1 -0.45 (-1.73, 0.84) 0.21 (-1.19, 1.60) 0.648 
Model 2 -0.73 (-2.03, 0.57) 0.26 (-1.13, 1.65) 0.376 
Model 3 -0.91 (-2.20, 0.37) 0.29 (-1.08, 1.65) 0.214 
Model 4 -0.76 (-2.00, 0.49) 0.04 (-1.30, 1.37) 0.412 
Model 5 -0.83 (2.06, 0.40) 0.08 (-1.23, 1.40) 0.318 
Model 6 -0.66 (-1.92, 0.61) 0.17 (-1.20, 1.54) 0.456 
Model 7 -0.50 (-1.79, 0.78) 0.19 (-1.20, 1.58) 0.607 
Model 8 -0.99 (-2.21, 0.23) 0.09 (-1.18, 1.37) 0.190 
Model 9 -1.09 (-2.32, 0.13) 0.13 (-1.15, 1.40) 0.140 
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^Reference category: 7 hours 
Model 1 adjusted for age 
Model 2 adjusted for age and baseline weight/percentage body fat  
Model 3 adjusted for age, baseline weight/percentage body fat, insomnia, and aMT6s 
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status 
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly 
energy expenditure 
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning 
and emotional limitations constructs  
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol 
consumption Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke  
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8 
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8 
 
  
Table 6. Multivariable linear regression describing influence of baseline sleep duration on body 
weight at year 6, N=547 
 Sleep duration, ≤6 hours^ Sleep duration, ≥8 hours^  
 β (95% CI) β (95% CI) P Value 
Unadjusted 2.22 (-1.16, 5.60) 1.51 (-2.14, 5.17) 0.413 
Model 1 2.04 (-1.28, 5.36) 1.50 (-2.09, 5.09) 0.452 
Model 2 0.51 (-1.38, 2.40) -0.64 (-2.68, 1.40) 0.574 
Model 3 0.44 (-1.48, 2.36) -0.59 (-2.64, 1.46) 0.656 
Model 4 0.40 (-1.51, 2.32) -0.70 (-2.74, 1.34) 0.602 
Model 5 0.56 (-1.36, 2.48) -0.58 (-2.64, 1.48) 0.588 
Model 6 0.41 (-1.51, 2.33) -0.69 (-2.74, 1.36) 0.604 
Model 7 0.49 (-1.40, 2.39) -0.66 (-2.71, 1.40) 0.575 
Model 8 0.54 (-1.36, 2.54) -0.64 (-2.69, 1.40) 0.559 
Model 9 0.54 (-1.44, 2.53)  -0.71 (-2.80, 1.37) 0.539 
Model 10 0.56 (-1.44, 2.56) -0.71 (-2.80, 1.37) 0.539 
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     ^Reference category: 7 hours 
Model 1 adjusted for age 
Model 2 adjusted for age and baseline weight/percentage body fat  
Model 3 adjusted for age, baseline weight/percentage body fat, insomnia, and aMT6s 
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status 
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly 
energy expenditure 
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning 
and emotional limitations constructs  
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol 
consumption Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke  
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8 
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8 
 
  
Table 7.  Multivariable linear regression describing influence of baseline sleep duration on body 
fat  percentage at year 6, N=529 
 Sleep duration, ≤6 hours^ Sleep duration, ≥8 hours^  
 β (95% CI) β (95% CI) P Value 
Unadjusted  -0.24 (-1.77, 1.29) 0.69 (-0.96, 2.34) 0.559 
Model 1 -0.28 (-1.80, 1.25) 0.68 (-0.98, 2.32) 0.545 
Model 2 -0.07 (-0.86, 0.71) -0.45 (-1.30, 0.40) 0.568 
Model 3 -0.13 (-0.93, 0.66) -0.42 (-1.27, 0.44) 0.631 
Model 4 -0.01 (-0.82, 0.79) -0.38 (-1.23, 0.48) 0.653 
Model 5 -0.03 (-0.83, 0.77) -0.39 (-1.34, 0.46) 0.631 
Model 6 -0.14 (-0.94, 0.66) -0.50 (-1.35, 0.36) 0.517 
Model 7 -0.11 (-0.91, 0.68) -0.45 (-1.32, 0.41) 0.577 
Model 8 -0.06 (-0.85, 0.73) -0.45 (-1.30, 0.40) 0.560 
Model 9 -0.08 (-0.91, 0.75) -0.39 (-1.26, 0.48) 0.669 
Model 10 -0.11 (-0.95, 0.73)  -0.38 (-1.26, 0.49) 0.685 
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Table 8. Sleep insomnia status by study population characteristics in the Women’s 
Health Initiative, n=690 
Characteristic  No Insomnia 
N=481 
Insomnia 
N=209 P-value 
n (%) /Mean±SD n (%) /Mean±SD 
Age in years    
   ≤59 150 (31.2) 71 (34.0) >0.1 
   60-69 239 (49.7) 94 (45.0)  
   ≥70 92 (19.1) 44 (21.0)  
Body Mass Index (kg/m2)    
    Normal Weight (<25 kg/m2) 186 (38.7) 73 (34.9) >0.1 
    Overweight (25 to <30 kg/m2) 162 (33.7) 77 (36.8)  
    Obese (≥30 kg/m2) 133 (27.6) 59 (28.3)  
aMT6s (ng/mg creatinine) 2.4±1.0 2.5±0.9 >0.1 
Sleep Duration    
    6 hours or less 124 (25.8) 105 (50.2) <0.001 
    7 hours 208 (43.2) 77 (36.8)  
    8 hours or more 149 (31.0) 27 (12.9)  
Body Fat Percentage 30.6±3.8 31.0±3.9 >0.1 
Whole Body Fat Mass (g) 31.3±11.1 32.4±12.0 >0.1 
Whole Body Lean Mass (g) 37.8±5.2 38.3±5.3 >0.1 
Education    
  Less than High School 31 (6.4) 15 (7.2) 
>0.1 
  High School to <College 148 (30.8) 81 (38.7) 
  College to <Post-grad Study 178 (37.0) 61 (29.2) 
  ≥Post-grad Study or Degree 124 (25.8) 52 (24.9) 
Ethnicity    
White (Non-Hispanic) 396 (82.3) 172 (82.3) 
0.06 
Black or African-American  
(Non-Hispanic) 
50 (10.4) 30 (14.3) 
   Other 35 (7.3) 7 (3.4) 
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Income Status    
    <$35,000 218 (49.0) 105 (53.8) >0.1 
    $35,000-<$75,0000 160 (36.0) 67 (34.4)  
    ≥ $75,000 67 (15.1) 23 (11.8)  
Employment Status   
>0.1     Not employed 264 (66.2) 123 (71.1) 
    Employed 135 (33.8) 50 (28.9) 
Marital Status   
<0.05 
Never Married 22 (4.6) 4 (1.9) 
     Widowed/Divorced/Separated 136 (28.3) 76 (36.4) 
Married/Marriage-like 
relationship 
323 (67.1) 129 (61.7) 
Total Caloric Intake (kcal/day)    
   Tertile 1 (168.1-1158.5) 163 (33.8) 67 (32.1) 
>0.1    Tertile 2 (1159.4-1618.9) 159 (33.1) 74 (35.4) 
   Tertile 3 (1621.0-6497.7) 159 (33.1) 68 (32.5) 
Modified Healthy Eating Index    
   Tertile 1 (27.3-65.8) 151 (31.4) 79 (37.8) 
>0.1    Tertile 2 (65.9-74.7) 160 (33.3) 69 (33.0) 
   Tertile 3 (74.7-90.4) 170 (35.3) 61 (29.2) 
Diagnosis of Diabetes    
     No 452 (94.0) 198 (94.7) >0.1 
     Yes 29 (6.0) 11 (5.3)  
Diagnosis of Stroke   
>0.1      No 478 (99.4) 208 (99.2) 
     Yes 3 (0.6) 1 (0.5) 
Diagnosis of MI   
>0.1      No 468 (97.3) 204 (97.6) 
     Yes 13 (2.7) 5 (2.4) 
Cigarette smoking   
>0.1 
    Never 266 (55.3) 99 (47.4) 
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    Former 180 (37.4) 97 (46.4) 
    Current 35 (7.3) 13 (6.2) 
Alcohol consumption   
>0.1 
    Non drinker 77 (16.0) 32 (15.3) 
    Past drinker 94 (19.6) 47 (22.5) 
Current Drinkers   
    <1 drink per month 65 (13.5) 27 (12.9) 
    <1 drink per week 93 (19.3) 38 (18.2) 
    1 to <7 drinks per week 110 (22.9) 41 (19.6) 
    7+ drinks per week 42 (8.7) 24 (11.5) 
Caffeine Consumption (mg) 172.7±136.6 161.9±132.4 >0.1 
Energy expenditure from 
physical activity (METS hr/wk) 
12.3±13.5 13.1±15.1 >0.1 
Social Strain 6.3±2.4 6.7±2.7 >0.1 
Physical Functioning 83.5±17.3 75.2±22.8 <0.001 
Depressive Symptoms    
    No  (<0.06) 452 (94.0) 158 (75.6) 
<0.001 
    Yes (≥0.06) 29 (6.0) 51 (22.4) 
Limitations due to emotional 
problems 
89.5±23.3 71.6±39.5 <0.001 
 a METS (metabolic equivalent task scores) 
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Table 9. Multivariable linear regression describing influence of baseline insomnia status on baseline 
body mass index and percent body fat^ 
 Body Mass Index (kg/m2) 
N=690 
Body Fat Percentage 
N=684 
 β (95% CI) P Value β (95% CI) P Value 
Unadjusted 0.04 (-0.09, 0.17) 0.517 0.45 (-0.75, 1.66) 0.458 
Model 1 0.04 (-0.09, 0.17) 0.525 0.45 (-0.75, 1.65) 0.459 
Model 2 0.05 (-0.08, 0.19) 0.441 0.71 (-0.52, 1.94) 0.257 
Model 3 0.03 (-0.10, 0.16) 0.663 0.39 (-0.80, 1.58) 0.524 
Model 4 0.04 (-0.09, 0.17) 0.525 0.43 (-0.72, 1.58) 0.466 
Model 5 -0.05 (-0.18, 0.08) 0.482 -0.19 (-1.39,1.01) 0.759 
Model 6 0.02 (-0.11, 0.15) 0.762 0.31 (-0.87, 1.50) 0.600 
Model 7 0.05 (-0.08, 0.18) 0.474 0.48 (-0.72, 1.68) 0.431 
Model 8 -0.04 (-0.17, 0.09) 0.535 0.04 (-0.13, 1.21) 0.949 
Model 9 -0.02 (-0.15, 0.11) 0.736 0.32 (-0.88, 1.52) 0.603 
^Reference category: no insomnia 
Model 1 adjusted for age 
Model 2 adjusted for age, sleep duration, and aMT6s 
Model 3 adjusted for age, education, ethnicity, and marital status 
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure 
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional limitations 
constructs  
Model 6 adjusted for age, smoking status, alcohol consumption  
Model 7 adjusted for age, diabetes, and stroke  
Model 8 adjusted for age, all variables from weight models 3-7 
Model 9 adjusted for age, all variables from weight models 2-7 
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Table 10. Multivariable linear regression describing influence of baseline insomnia status on 
body weight and body fat percent at year 6 
 Body Weight (kg)^ 
N=547 
Body Fat Percentage (%)^ 
N=529 
 β (95% CI) P Value β (95% CI) P Value 
Unadjusted 2.33 (-0.85, 5.52) 0.151 1.12 (-0.32, 2.56) 0.128 
Model 1 2.12 (-1.01, 5.25) 0.185 1.06 (-0.38, 2.49) 0.149 
Model 2 0.75 (-1.03, 2.53) 0.410 0.58 (-0.16, 1.32) 0.124 
Model 3 0.55 (-1.29, 2.38) 0.558 0.52 (-0.24, 1.28) 0.176 
Model 4 0.51 (-1.29, 2.31) 0.576 0.46 (-0.29, 1.21) 0.225 
 
Model 5 0.80 (-0.99, 2.59) 0.379 0.56 (-0.18, 1.30) 0.136 
Model 6 0.53 (-1.36, 2.43) 0.579 0.58 (-0.22, 1.37) 0.154 
Model 7 0.50 (-1.29, 2.29) 0.583 0.58, (-0.17, 1.33) 0.128 
Model 8 0.75 (-1.03, 2.54) 0.406 0.59 (-0.15, 1.33) 0.118 
Model 9 0.25 (-1.69, 2.19) 0.799 0.40 (-0.42, 1.21) 0.339 
Model 10 0.02 (-1.96, 2.00) 0.983 0.34 (-0.49, 1.17) 0.424 
^Reference category: no insomnia 
Model 1 adjusted for age 
Model 2 adjusted for age and baseline weight/percentage body fat  
Model 3 adjusted for age, baseline weight/percentage body fat, sleep duration, and aMT6s 
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status 
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly energy 
expenditure 
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning 
and emotional limitations constructs  
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol consumption 
Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke  
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8 
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8 
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Table 11. Urinary Levels of Melatonin Metabolite by study population characteristics in 
the Women’s Health Initiative, N=690 
Characteristic 
 aMT6s (ng/mg creatinine) 
P-Value 
Geometric Mean 95%CI 
Age (years)    
   ≤59 12.8 (11.2, 14.6) 0.01 
   60-69 11.8  (10.6, 13.0)  
   ≥70 9.8 (8.4, 11.5)  
Body Mass Index (kg/m2)   
    Normal Weight (<25 kg/m2) 14.2 (12.7, 15.8) 
<0.001     Overweight (25 to <30 kg/m2) 10.9 (9.7, 12.3) 
    Obese (≥30 kg/m2) 9.7 (8.4, 11.2) 
Sleep Duration   
    6 hours or less 10.7 (9.4, 12.2) >0.1 
    7 hours 12.3 (11.1, 13.6)  
    8 hours or more 11.9 (10.2, 13.9)  
Insomnia    
    No (<9) 11.5 (10.6, 12.6) >0.1 
    Yes (≥9) 12.0 (10.6, 13.6)  
Education  
0.01 
    Less than High School 7.8 (5.9, 10.4) 
    High School to <College 11.5 (10.2, 13.0) 
    College to <Post-grad Study 11.8 (10.5, 13.4) 
    ≥Post-grad Study or Degree 13.0 (11.3, 14.8) 
Ethnicity   
    White (Non-Hispanic) 12.3 (11.4, 13.3) 
0.001     Black or African-American (Non-Hispanic) 8.1 (6.4, 10.3) 
    Other 11.4 (8.7, 15.0) 
Income Status  
>0.1     <$35,000 11.4 (10.3, 12.6) 
    $35,000 - $75,0000 12.3 (10.8, 14.0) 
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    ≥ $75,000 11.6 (9.4, 14.3) 
Employment Status  
>0.1     Not employed 11.4 (10.4, 12.5) 
    Employed 11.7 (10.1, 13.5) 
Marital Status  
>0.1 
    Never Married 12.1 (8.4, 17.3) 
    Widowed/Divorced/Separated 10.4 (9.1, 11.8) 
    Married/Marriage-like relationship 12.3 (11.3, 13.4) 
Total Caloric Intake (kcal/day)   
   Tertile 1 (168.1-1158.5) 11.1 (9.8, 12.6) >0.1 
   Tertile 2 (1159.4-161 8.9) 11.6 (10.2, 13.1)  
   Tertile 3 (1621.0-6497.7) 12.4 (10.9, 14.0)  
Modified Healthy Eating Index   
   Tertile 1 (27.3-65.8) 10.7 (9.4, 12.2) >0.1 
   Tertile 2 (65.9-74.7) 11.8 (10.4, 13.4)  
   Tertile 3 (74.7-90.4) 12.6 (11.2, 14.1)  
Prior Diagnosis of Diabetes   
     No 12.1 (11.3, 17.8) <0.001 
     Yes 6.4 (4.3, 9.5)  
History of Stroke   
     No 11.7 (10.9, 12.6) 0.02 
     Yes 3.8 (0.6, 22.7)  
History of MI   
     No 11.8 (10.9, 12.6) >0.1 
     Yes 8.6 (4.8, 15.1)  
Cigarette smoking   
    Never 11.6 (10.6, 12.7) >0.1 
    Former 11.8 (10.5, 13.2)  
    Current 11.4 (8.1, 16.2)  
Alcohol consumption   
    Non drinker 11.4 (9.4, 13.6) 0.06 
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    Former drinker 9.5 (8.0, 11.3)  
Current drinker    
    <1 drink per month 13.6 (11.6, 16.0)  
    <1 drink per week 12.7 (10.9, 14.9)  
    1 to <7 drinks per week 12.1 (10.4, 14.2)  
    7+ drinks per week 11.8 (9.4, 14.7)  
Depressive Symptoms   
     No  (<0.06) 11.6 (10.7, 12.5) > 0.1 
     Yes (≥0.06) 12.5 (10.0, 15.7)  
 Correlation with aMT6s P-Value 
Body Fat Percentage -0.147 <0.001 
Whole Body Fat Mass (kg) -0.173 <0.001 
Whole Body Lean Mass (kg) -0.165 <0.001 
Caffeine Consumption (mg) 0.054 >0.1 
Energy expenditure from physical activity 
(METSa hr/wk) 
0.055 
>0.1 
Social Strain -0.018 >0.1 
Physical Functioning 0.114 <0.001 
Limitations due to emotional problems -0.009 >0.1 
 a METS (metabolic equivalent task scores) 
 
  
41 
 
Table 12. Multivariable linear regression describing influence of baseline creatinine-adjusted 
melatonin metabolite (ng/mg of creatinine) on baseline body mass index and body fat percentage 
 Body Mass Index (kg/m2) 
N=690 
Body Fat Percentage  
N=684 
 β (95% CI) P Value β (95% CI) P Value 
Unadjusted -0.14 (-0.20, -0.07) <0.001 -1.03 (-1.61, -0.45) 0.001 
Model 1 -0.14 (-0.20, -0.08) <0.001 -1.04 (-1.62, -0.46) <0.001 
Model 2 -0.14 (-0.20, -0.08) <0.001 -1.07 (-1.65, -0.49) <0.001 
Model 3 -0.11 (-0.17, -0.05) 0.001 -0.84 (-1.42, -0.26) 0.005 
Model 4 -0.13 (-0.19, -0.06) <0.001 -0.84 (-1.40, -0.28) 0.004 
Model 5 -0.10 (-0.16, -0.05) 0.001 -0.73 (-1.28, -0.17) 0.010 
Model 6 -0.13 (-0.19, -0.07) <0.001 -0.98 (-1.55, -0.40) 0.001 
Model 7 -0.12 (-0.19, -0.06) <0.001 -0.95 (-1.54, -0.36) 0.002 
Model 8 -0.09 (-0.15, -0.03) 0.004 -0.61 (-1.16, -0.06) 0.029 
Model 9 -0.09 (-0.15, -0.03) 0.004 -0.63 (-1.18, -0.08) 0.024 
Model 1 adjusted for age 
Model 2 adjusted for age, insomnia, and sleep duration, 
Model 3 adjusted for age, education, ethnicity, and marital status 
Model 4 adjusted for age, HEI score, dietary energy, and weekly energy expenditure 
Model 5 adjusted for age, depressive symptom status, physical functioning and emotional limitations 
constructs  
Model 6 adjusted for age, smoking status, alcohol consumption  
Model 7 adjusted for age, diabetes, and stroke  
Model 8 adjusted for age, all variables from weight models 3-7 
Model 9 adjusted for age, all variables from weight models 2-7 
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Table 13. Multivariable linear regression describing influence of baseline creatinine-adjusted 
melatonin metabolite (ng/mg of creatinine) on body weight and body fat percentage at year 6 
 Body Weight (kg) 
N=543 
Body Fat Percentage (%) 
N=525 
 β (95% CI) P Value β (95% CI) P Value 
Unadjusted -1.53 (-3.15, 0.08) 0.062 -0.34 (-1.07, 0.38) 0.354 
Model 1 -1.79 (-3.38, -0.20) 0.027 -0.40 (-1.13, 0.32) 0.277 
Model 2 0.34 (-0.40, 1.09) 0.362 0.33 (-0.05, 0.70) 0.089 
Model 3 0.33 (-0.41, 1.08) 0.379 0.32 (-0.05, 0.70) 0.091 
Model 4 0.36 (-0.39, 1.11) 0.344 0.31 (-0.07, 0.70) 0.109 
Model 5 0.36 (-0.39, 1.10) 0.347 0.32 (-0.05, 0.70) 0.089 
Model 6 0.35 (-0.40, 1.10) 0.355 0.33 (-0.05, 0.70) 0.089 
Model 7 0.32 (-0.44, 1.07) 0.407 0.32 (-0.06, 0.71) 0.094 
Model 8 0.38 (-0.37, 1.13) 0.320 0.34 (-0.04, 0.72) 0.079 
Model 9 0.41 (-0.36, 1.17) 0.299 0.33 (-0.06, 0.72) 0.101 
Model 10 0.40 (-0.37, 1.17) 0.305 0.33 (-0.06, 0.72) 0.098 
Model 1 adjusted for age 
Model 2 adjusted for age and baseline weight/percentage body fat  
Model 3 adjusted for age, baseline weight/percentage body fat, insomnia, and sleep duration 
Model 4 adjusted for age, baseline weight/percentage body fat, education, ethnicity, and marital status 
Model 5 adjusted for age, baseline weight/percentage body fat, HEI score, dietary energy, weekly energy 
expenditure 
Model 6 adjusted for age, baseline weight/percentage body fat, depression status, physical functioning 
and emotional limitations constructs  
Model 7 adjusted for age, baseline weight/percentage body fat, smoking status, and alcohol consumption 
Model 8 adjusted for age, baseline weight/percentage body fat, diabetes, and stroke  
Model 9 adjusted for age, baseline weight/percentage body fat, all variables from weight models 4-8 
Model 10 adjusted for age, baseline weight/percentage body fat, all variables from weight models 3-8 
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Figure 1: Mixed model regression describing influence of baseline aMT6s on body fat 
percentage at baseline, year 3, and year 6  
 
 
  
44.82281448
45.0652736
44.34257272
43.03718748
43.81000175
43.61765603
41.23201266
42.54098805
42.88480344
41
41.5
42
42.5
43
43.5
44
44.5
45
45.5
0 1 2 3 4 5 6 7
B
o
d
y 
Fa
t 
P
er
ce
n
at
ge
Year
Triennial variations in body fat percentage by baseline melatonin 
metabolite (age-adjusted)
LnMelatonin=0
LnMelatonin=2
LnMelatonin=4
44 
 
Figure 2: Mixed model regression describing influence of baseline aMT6s on weight at 
baseline, year 3, and year 6  
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